Training Program on HIV Diversity and Drug Resistance-Enhancing Research Capacity

项目摘要/摘要 喀麦隆广泛的艾滋病毒-1基因多样性和抗药性变异株的出现增加了 使病毒遗传多样性复杂化，并给诊断和预防工作带来潜在问题， 要求监测艾滋病毒-1多样性的演变，并检查新的艾滋病毒-1变种 不同HIV-1检测试剂盒检测的敏感性。这些问题继续强调有必要进一步 在喀麦隆的培训和研究。这项名为“艾滋病毒多样性和毒品问题培训方案”的培训方案 阻力：提升研究能力“是为建设和加强研究能力而设计的 在喀麦隆雅温得的医疗诊断中心进行研究，以记录和监测 艾滋病毒-1基因多样性和进化；2)记录和监测抗逆转录病毒耐药性的出现 HIV-1变异体；3)研究不同HIV-1变异体的生物学和免疫学特性 和耐药菌株；4)监测市场上可获得的检测试剂盒诊断感染的能力 由不同的HIV-1毒株引起的；和5)提高质量保证和实验室生物安全。 为实现这些目标，我们将：a)组织国内培训讲习班，提供短期当地培训 关于以下方面的现场培训：一)质量保证和实验室生物安全；二)新技术和商业 现有检测试剂盒，用于诊断各种艾滋病毒毒株引起的感染；以及三)科学和赠款 写作技巧。B)在纽约为分子研究提供长期培训 与非学位或学位的艾滋病毒遗传多样性研究有关的生物学/流行病学/生物统计学 面向博士后和博士后研究员的课程。C)在纽约为研究员提供中期培训，以 进行有关病毒基因亚型表征和计算分析的动手实验室培训 记录和确定不同的艾滋病毒-1毒株和/或耐药性突变，以及病毒生物学和 免疫学特性。D)通过记录药物的实际培训提供短期培训 耐药突变和数据解释，参加流行病学和生物统计学课程并工作 与相关导师一对一交流。以及，e)通过提供小额赠款支持国内研究 聘请适当的长期“校友”研究员进行研究，以实现争取民主变革运动的研究目标。这 培训方案应建立和加强MDC进行艾滋病毒-1研究的研究能力 与喀麦隆的干预和预防方案相关的多样性和耐药性。

Project Summary /Abstract The broad HIV-1 genetic diversity and the emergence of drug resistant variants in Cameroon adds to complicate the viral genetic diversity and poses potential problems for diagnosis and prevention efforts, requiring that the evolution of HIV-1 diversity be monitored, and that new HIV-1 variants be examined for sensitivity of detection by different HIV-1 test kits. These problems continue to underscore the need for further training and research in Cameroon. This training program entitled "Training Program on HIV Diversity and Drug Resistance: enhancing research capacity" is designed with long-term to build and strengthen research capacity at the Medical Diagnostic Center in Yaounde, Cameroon for conducting studies to 1) document and monitor HIV-1 genetic diversity and evolution; 2) document and monitor the emergence antiretroviral drug resistant HIV-1 variants; 3) study the biologic and immunologic properties of different HIV-1 variants including emerging and drug resistant strains; 4) monitor the ability of commercially available test kits to diagnose infections by caused by diverse HIV-1 strains; and 5) to improve quality assurance and laboratory biosafety. To achieve these objectives we will: a) Organize in-country training workshops that will provide short-term local onsite training on: i) quality assurance and laboratory biosafety; ii) new technologies and commercially available test kits for the diagnosis of infections caused by diverse HIV strains; and iii) scientific and grant writing skills. b) Provide long-term training in New York for studies of molecular biology/epidemiology/biostatistics relevant to studies of HIV genetic diversity through non-degree or degree programs for pre- and post-doctoral fellows. c) Provide medium-term training in New York for fellows to perform hands-on-laboratory training on viral genetic subtype characterization and computational analysis to document and identify diverse HIV-1 strains and/or drug resistance mutations, and viral biologic and immunologic properties. d) Provide short-term training through hands-on-training in documenting drug resistance mutations and data interpretation, to attend courses on epidemiology and biostatistics and to work one-on-one with relevant mentors. And, e) To support in-country research by providing small grants to appropriate long-term "alumni" fellows to conduct studies that addresses the research goals of the MDC. This training program should build and strengthen the research capacity at MDC to conduct studies on HIV-1 diversity and drug resistance that are relevant to intervention and prevention programs in Cameroon.